DK0517895T3 - Kimæriske kæder til receptorforbundne signaltransduktionsveje - Google Patents

Kimæriske kæder til receptorforbundne signaltransduktionsveje

Info

Publication number
DK0517895T3
DK0517895T3 DK92903452.8T DK92903452T DK0517895T3 DK 0517895 T3 DK0517895 T3 DK 0517895T3 DK 92903452 T DK92903452 T DK 92903452T DK 0517895 T3 DK0517895 T3 DK 0517895T3
Authority
DK
Denmark
Prior art keywords
receptor
chimeric proteins
signal transduction
signalling pathway
transduction pathways
Prior art date
Application number
DK92903452.8T
Other languages
English (en)
Inventor
Daniel J Capon
Arthur Weiss
Brian A Irving
Original Assignee
Univ California
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24515497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0517895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Cell Genesys Inc filed Critical Univ California
Application granted granted Critical
Publication of DK0517895T3 publication Critical patent/DK0517895T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK92903452.8T 1990-12-14 1991-12-12 Kimæriske kæder til receptorforbundne signaltransduktionsveje DK0517895T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62764390A 1990-12-14 1990-12-14

Publications (1)

Publication Number Publication Date
DK0517895T3 true DK0517895T3 (da) 1997-04-07

Family

ID=24515497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92903452.8T DK0517895T3 (da) 1990-12-14 1991-12-12 Kimæriske kæder til receptorforbundne signaltransduktionsveje

Country Status (13)

Country Link
US (1) US5359046A (da)
EP (2) EP0732402A3 (da)
JP (1) JP3242916B2 (da)
KR (1) KR100246529B1 (da)
AT (1) ATE145428T1 (da)
AU (1) AU643109B2 (da)
CA (1) CA2074825C (da)
DE (1) DE69123241T2 (da)
DK (1) DK0517895T3 (da)
ES (1) ES2096749T3 (da)
GR (1) GR3022538T3 (da)
NO (1) NO308618B1 (da)
WO (1) WO1992010591A1 (da)

Families Citing this family (382)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
DE69131564T2 (de) * 1990-07-20 2000-01-13 Bayer Ag Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6407221B1 (en) * 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Change of direction of cellular immunity by chimera receptors
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) * 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
AU685054C (en) * 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
CA2170980A1 (en) * 1993-09-03 1995-03-09 James Mule Genetically modified human hematopoietic stem cells and their progeny
AU2207195A (en) * 1994-04-05 1995-10-23 Board Of Regents, The University Of Texas System Modified receptors that continuously signal
DK0758394T3 (da) 1994-05-02 2003-03-03 Bernd Groner Bifunktionelt protein, fremstilling og anvendelse
US5972627A (en) * 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5985660A (en) * 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
WO1996013584A1 (en) * 1994-11-01 1996-05-09 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
DE69634855T2 (de) * 1995-02-24 2006-05-18 The General Hospital Corp., Boston Neuorientierung der zellulären immunität durch rezeptorchimären
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
CA2217297A1 (en) * 1995-04-04 1996-10-10 Cell Genesys, Inc. Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface
US5866416A (en) * 1995-04-07 1999-02-02 The United States Of America As Represented By The Secretary Of Agriculture Cell line for propagating receptor binding site-deleted FMDV
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6015554A (en) * 1995-06-07 2000-01-18 Systemix, Inc. Method of reconstituting human lymphoid and dendritic cells
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6017754A (en) * 1995-08-24 2000-01-25 Invitrogen Corporation System for isolating and identifying eukaryotic cells transfected with genes and vectors, host cells and methods thereof
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
US6699715B1 (en) 1995-11-30 2004-03-02 Bristol-Myers Squibb Co. Modified sFv molecules which mediate adhesion between cells and uses thereof
WO1997020048A2 (en) * 1995-11-30 1997-06-05 Bristol-Myers Squibb Company Modified sfv molecules which mediate adhesion between cells and uses thereof
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
WO1997039021A1 (en) * 1995-12-21 1997-10-23 The Scripps Research Institute Targeted therapeutic or diagnostic agents and methods of making and using same
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7148004B1 (en) * 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
US7084252B1 (en) * 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US7619079B2 (en) * 1996-02-14 2009-11-17 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
CA2248142A1 (en) * 1996-03-12 1997-09-18 Life Technologies, Inc. Hematopoietic cell culture nutrient supplement
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6060054A (en) 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
AU2728297A (en) * 1996-04-15 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain G-protein-coupled receptor compositions and me thods
AU744160B2 (en) * 1996-10-25 2002-02-14 Cell Genesys, Inc. Targeted cytolysis of cancer cells
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
AU750358B2 (en) 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
GB9809658D0 (en) * 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
WO2000023573A2 (en) * 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
ATE370967T1 (de) * 1998-10-21 2007-09-15 Altor Bioscience Corp Polyspezifische bindemoleküle und deren verwendung
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6200803B1 (en) 1999-05-21 2001-03-13 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6221597B1 (en) 1999-05-21 2001-04-24 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6197517B1 (en) 1999-05-21 2001-03-06 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
BR0012195A (pt) * 1999-06-25 2002-07-23 Genentech Inc Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6632628B1 (en) 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
WO2002043660A2 (en) 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
ATE473751T1 (de) * 2000-02-11 2010-07-15 Schepens Eye Res Inst Isolierung und transplantation von retinalen stammzellen
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
KR101135233B1 (ko) * 2000-05-19 2012-04-12 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
IL136511A0 (en) 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
EP2281843B1 (en) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
CA2425862C (en) * 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US7511121B2 (en) 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
CA2442971C (en) * 2001-04-06 2011-06-07 University Of Chicago Chemotherapeutic induction of egr-1 promoter activity
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US7514537B2 (en) * 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
AU2007237297B2 (en) * 2001-04-30 2010-12-16 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US11278594B2 (en) 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030171546A1 (en) * 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
DK1572874T3 (da) 2001-05-25 2013-12-16 Human Genome Sciences Inc Antistoffer, der immunospecifikt binder til TRAIL receptorer
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20030148982A1 (en) * 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
JP2005523688A (ja) * 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
CA2480052A1 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
CA2481747A1 (en) 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
ES2627445T3 (es) 2002-05-01 2017-07-28 Miltenyi Biotec Technology, Inc. Partículas de vector de lentivirus resistentes a la inactivación por el complemento
US20040091486A1 (en) 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003275985A1 (en) * 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
AU2003265454A1 (en) * 2002-08-16 2004-03-03 Ohio University Hepatitis c viral-like particle purification
CA2502367C (en) 2002-10-16 2013-12-10 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
WO2004043397A2 (en) * 2002-11-12 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of rheumatoid arthritis
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) * 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
EP1585815A4 (en) * 2003-01-21 2006-02-22 Bristol Myers Squibb Co A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US20070212298A1 (en) * 2004-08-25 2007-09-13 Prefix Suffix Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20080112933A1 (en) * 2004-11-08 2008-05-15 Scadden David T Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators
RU2393874C2 (ru) * 2005-02-01 2010-07-10 Рисерч Дивелопмент Фаундейшн Полипептиды с направленным действием
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP1931700B1 (en) 2005-05-19 2013-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007008604A2 (en) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
WO2007056352A2 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
AU2007244683A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
JP5764290B2 (ja) 2006-06-26 2015-08-19 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体およびその使用法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
ES2519375T3 (es) 2006-09-01 2014-11-06 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
US8105575B2 (en) 2006-10-10 2012-01-31 Viromed Co., Ltd. Expression vectors with improved safety
US20100143254A1 (en) 2006-10-16 2010-06-10 Medimmune, Llc Molecules with reduced half-lives, compositions and uses thereof
AU2007353396C1 (en) 2006-11-02 2013-06-27 Biomolecular Holdings Llc Hybrid immunoglobulins with moving parts
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
EP2077859A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODY FORMULATION
ES2540807T3 (es) 2007-05-04 2015-07-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
NO3072525T3 (da) 2007-05-14 2018-06-30
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
CN101861391A (zh) 2007-08-10 2010-10-13 韦恩州立大学 通过翻译调控基因表达系统检测和调节细胞死亡的组合物和方法
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008333131B2 (en) 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
US20090181409A1 (en) * 2008-01-10 2009-07-16 Ye Fang Optical biosensor method for cell-cell interaction
MX2010007767A (es) 2008-01-18 2010-08-09 Medimmune Llc Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
WO2011011027A1 (en) 2009-07-20 2011-01-27 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
EP2328928A2 (en) 2008-08-25 2011-06-08 Dana-Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
ES2548030T3 (es) 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
CA2770737C (en) * 2009-08-13 2020-05-12 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US9428583B2 (en) 2010-05-06 2016-08-30 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
RU2592672C9 (ru) 2010-12-08 2016-11-27 СтемСентРкс, Инк. Новые модуляторы и способы их применения
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2758422A1 (en) 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Modified albumin-binding domains and uses thereof to improve pharmacokinetics
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2773665A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
CN104080811B (zh) 2011-11-04 2019-09-27 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TW201323442A (zh) 2011-11-04 2013-06-16 Novartis Ag 低密度脂蛋白相關蛋白６（ｌｒｐ６）－半衰期延長構築體
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
TW201328707A (zh) 2011-12-05 2013-07-16 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之區域ｉｉ之ｈｅｒ３抗體
CN104159924B (zh) 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2864818C (en) 2012-02-17 2022-05-03 The Schepens Eye Research Institute Phenotype profile of human retinal progenitor cells
SG10201801444WA (en) 2012-02-24 2018-04-27 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
WO2013126746A2 (en) 2012-02-24 2013-08-29 Stem Centrx, Inc. Novel modulators and methods of use
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2013176916A1 (en) 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
MX368067B (es) 2012-12-05 2019-09-18 Novartis Ag Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
US20150329640A1 (en) * 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
CA2901115A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of California Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof
RU2708032C2 (ru) 2013-02-20 2019-12-03 Новартис Аг ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
CN105164159A (zh) 2013-02-22 2015-12-16 施特姆森特克斯股份有限公司 新的抗体缀合物及其用途
JP2016514130A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
DK2970473T3 (da) 2013-03-14 2017-11-27 Bristol Myers Squibb Co Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
EP2968495B1 (en) 2013-03-15 2019-07-03 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
CN105848671B (zh) 2013-08-28 2019-12-13 艾伯维施特姆森特克斯有限责任公司 位点特异性抗体缀合方法和组合物
KR20160046914A (ko) 2013-08-28 2016-04-29 스템센트알엑스 인코포레이티드 신규한 ｓｅｚ6 조절물질 및 사용방법
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN111440813A (zh) * 2014-01-08 2020-07-24 北京强新生物科技有限公司 基于合成生物学的新型adcc技术
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3116486B1 (en) 2014-03-14 2019-12-04 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
AR101829A1 (es) 2014-07-21 2017-01-18 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
PE20170287A1 (es) 2014-08-07 2017-04-05 Novartis Ag Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
IL308324A (en) 2014-09-19 2024-01-01 Hope City IL13RA2-targeted chimeric antigen receptor T cells
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
US10688166B2 (en) 2014-11-03 2020-06-23 Cerus Corporation Compositions and methods for improved car-T cell therapies
RS63410B1 (sr) * 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods for preparing cells expressing a chimeric receptor antigen
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
US10195272B2 (en) * 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP4056588A1 (en) 2015-04-08 2022-09-14 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3291836A4 (en) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
DK3294764T3 (da) * 2015-05-15 2021-01-25 Hope City Kimæriske antigenreceptor sammensætninger
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
JP2018522540A (ja) 2015-06-05 2018-08-16 ノバルティス アーゲー 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
RU2752530C2 (ru) 2015-08-03 2021-07-29 Новартис Аг Способы лечения расстройств, связанных с fgf21
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US11352439B2 (en) * 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
KR20180042433A (ko) 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
AR106184A1 (es) 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
CA3003399A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー ＣＤ３２ｂを標的とする抗体およびその使用方法
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
CA3004491A1 (en) 2016-01-08 2017-07-13 The Regents Of The University Of California Conditionally active heterodimeric polypeptides and methods of use thereof
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
KR20220004226A (ko) 2016-03-22 2022-01-11 바이오노믹스 리미티드 항-lgr5 단클론성 항체의 투여
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102492057B1 (ko) 2016-06-15 2023-01-26 노파르티스 아게 골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
EP3481866A1 (en) 2016-07-06 2019-05-15 Bristol-Myers Squibb Company Combination of tim-4 antagonist and pd-1 antagonist and methods of use
EP3858365B1 (en) 2016-09-01 2024-01-31 Chimera Bioengineering Inc. Gold optimized car t-cells
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
WO2018116267A2 (en) 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
CN110612119A (zh) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US10899844B2 (en) 2017-02-08 2021-01-26 Novartis Ag FGF21 mimetic antibodies and uses thereof
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
RU2019133280A (ru) 2017-03-22 2021-04-22 Новартис Аг Композиции и способы для иммуноонкологии
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
MX2019011514A (es) 2017-03-27 2020-01-27 Nat Univ Singapore Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
EP3630813A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP7410856B2 (ja) 2017-07-18 2024-01-10 シーエスエル・ベーリング・ジーン・セラピー・インコーポレイテッド ドナー改変細胞の選択のための調節可能スイッチ
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
JP2021512147A (ja) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Ｃａｒ ｔ細胞の使用方法
JP2021514658A (ja) 2018-03-06 2021-06-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 前立腺特異的膜抗原ｃａｒおよびその使用方法
CN112004558A (zh) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
US11904081B2 (en) 2018-05-11 2024-02-20 Lupagen, Inc. Systems and methods for closed loop, real-time modifications of patient cells
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
AU2020279974A1 (en) 2019-05-21 2021-11-18 Novartis Ag CD19 binding molecules and uses thereof
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
AU2021207652B2 (en) 2020-01-14 2023-08-03 Synthekine, Inc. Biased IL2 muteins methods and compositions
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
TW202317190A (zh) 2021-06-29 2023-05-01 美商思進公司 以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法
TW202337904A (zh) 2022-01-07 2023-10-01 美商壯生和壯生企業創新公司 ＩＬ－１β結合蛋白之材料及方法
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
AU607306B2 (en) * 1988-02-02 1991-02-28 Regents Of The University Of California, The Human platelet-derived growth factor receptor
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
CA2000878C (en) * 1988-10-18 1999-06-29 Jean-Pierre Kinet Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e
WO1991010736A2 (en) * 1990-01-19 1991-07-25 Dana Farber Cancer Institute CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Change of direction of cellular immunity by chimera receptors
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith

Also Published As

Publication number Publication date
CA2074825A1 (en) 1992-06-15
DE69123241T2 (de) 1997-04-17
GR3022538T3 (en) 1997-05-31
EP0732402A2 (en) 1996-09-18
NO923171L (no) 1992-09-28
EP0732402A3 (en) 1997-05-21
AU9172291A (en) 1992-07-08
NO308618B1 (no) 2000-10-02
KR100246529B1 (ko) 2000-04-01
WO1992010591A1 (en) 1992-06-25
KR927003847A (ko) 1992-12-18
CA2074825C (en) 2005-04-12
EP0517895A4 (en) 1993-09-01
ATE145428T1 (de) 1996-12-15
EP0517895A1 (en) 1992-12-16
NO923171D0 (no) 1992-08-13
US5359046A (en) 1994-10-25
JPH05504262A (ja) 1993-07-08
ES2096749T3 (es) 1997-03-16
JP3242916B2 (ja) 2001-12-25
AU643109B2 (en) 1993-11-04
EP0517895B1 (en) 1996-11-20
DE69123241D1 (de) 1997-01-02

Similar Documents

Publication Publication Date Title
DK0517895T3 (da) Kimæriske kæder til receptorforbundne signaltransduktionsveje
HK31096A (en) Unique antigenic epitopes on ige-bearing b lymphocytes
DE3577564D1 (de) Polymere zur verwendung als hilfsmittel in der filtrationskontrolle fuer bohrfluessigkeiten.
AT359903B (de) Verfahren zur herstellung von aus kies mit kunstharz als bindemittel bestehenden platten und vorrichtung zur durchfuehrung des verfahrens
DE69506387T2 (de) Bindungstest unter verwendung von agenzien mit schwanzgruppen
DE69417037T2 (de) Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen
DE68911176D1 (de) Einrichtung zur Filtration von Flüssigkeiten.
DE968581T1 (de) Verwendung eines empfängermodels zum multiplexen von bitströmen variabler bitraten mit zeitlichen randbedingungen
DE69718969D1 (de) Stabilisierungsmittel zur Verhinderung von Gummibildung in Benzin
DE68929468D1 (de) An der Oberfläche verfärbungsbeständige, feuerhemmende Olefinharzzusammensetzung
DE69631406D1 (de) Verriegelungsschaltung zum Empfangen von Signalen mit niedriger Amplitude
DE68903181D1 (de) Polyimidharz-zusammensetzung.
DE69108206D1 (de) Gerät zum einpressen von flüssigkeit zur bodenverbesserung.
DE68910562D1 (de) Modifizierte Polypropylen-Harzzusammensetzung.
FR2711884B1 (fr) Dispositif de signalisation notamment pour la signalisation routière, aéronautique ou maritime.
DE68924764D1 (de) System zum Multiplexieren von Paketen bei der Übertragung von mittels des gleichen Algorithmus erzeugten Datenflüssen.
DE69622073T2 (de) Verwendung von Polyamidharzzusammensetzungen als Material zum Spritzgiessschweissen
DE59001699D1 (de) Vorrichtung zum querschneiden und querschweissen von bahnen.
PT1056850E (pt) Moleculas receptoras de ligacao a biotina
DE69407583T2 (de) Homogenes katalysator system zur hydrodechlorierung von chlorkohlenwasserstoffen
DE68916917D1 (de) Verfahren zur rückkehr zum ursprung.
SE9704919D0 (sv) Materials for screening of combinatorial libraries
Capon et al. Chimeric chains for receptor-associated signal transduction pathways
DE69625594T2 (de) Gerät zur Mitteilung den Anomalien von physikalischen Grössen
NO893798D0 (no) Forbedrede harpikser for anvendelse i gummi.